PepGen (PEPG)

Executive Summary

PepGen is a clinical-stage biotechnology company pioneering its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to overcome delivery barriers in muscle and nerve tissues. The lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), a severe neuromuscular disorder with no approved therapies. PGN-EDODM1 is currently in Phase 2 trials (NCT06667453 and NCT07220603), with data readouts anticipated in the second half of 2026. The platform's ability to penetrate skeletal and cardiac muscle positions it as a potential transformative therapy. However, past setbacks, including the termination of PGN-EDO51 in Duchenne muscular dystrophy (DMD) and withdrawal of a DMD infusion trial, underscore execution risks. Despite these, the DM1 program offers a clear regulatory pathway and significant unmet need. With a market cap of approximately $122 million, PepGen represents a high-risk, high-reward opportunity. Positive Phase 2 data would be a major de-risking event, potentially driving substantial upside. Key upcoming catalysts include topline results from the ongoing Phase 2 study and strategic updates on platform expansion.

Upcoming Catalysts (preview)

• Q3 2026Topline Phase 2 data for PGN-EDODM1 (NCT06667453)60% success
• Q1 2027Initiation of pivotal Phase 3 trial for PGN-EDODM150% success
• Q3 2026Regulatory update (e.g., FDA meeting or Fast Track designation)75% success